Federated Hermes Inc. Has $1.36 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Federated Hermes Inc. lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 41.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,051 shares of the company’s stock after selling 48,501 shares during the period. Federated Hermes Inc. owned about 0.14% of Enliven Therapeutics worth $1,359,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after purchasing an additional 2,630 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $112,000. Finally, ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics in the 4th quarter worth approximately $200,000. Institutional investors own 95.08% of the company’s stock.

Insider Transactions at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $19.79, for a total value of $131,939.93. Following the sale, the chief operating officer directly owned 296,642 shares in the company, valued at $5,870,545.18. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00. Following the completion of the transaction, the chief executive officer directly owned 940,392 shares of the company’s stock, valued at approximately $21,177,627.84. This trade represents a 1.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 99,084 shares of company stock worth $2,046,719. 25.90% of the stock is currently owned by insiders.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $18.84 on Thursday. The business’s 50-day simple moving average is $20.84 and its 200-day simple moving average is $20.05. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The stock has a market capitalization of $924.48 million, a PE ratio of -9.81 and a beta of 0.93.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

ELVN has been the topic of a number of recent research reports. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, July 2nd. Jones Trading decreased their price target on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th. The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Robert W. Baird increased their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, June 16th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $41.20.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.